SCHEMBL30765992

SCHEMBL30765992

COc1ccc(CNc2ncc(-c3ccccc3)n(CC(=O)O)c2=O)c(OC)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
CYP1A2 P05177 11/20 0.50
CYP3A4 P08684 11/20 0.50
CYP2C19 P33261 10/20 0.50
CYP2D6 P10635 10/20 0.50
CYP2C9 P11712 8/20 0.50
CLK4 Q9HAZ1 4/20 0.50
TSHR P16473 8/20 0.49
ALDH1A1 P00352 5/20 0.49
HIF1A Q16665 3/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.48
TP53 P04637 1/20 0.48
ALOX15 P16050 3/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
USP2 O75604 2/20 0.48
MAPK1 P28482 2/20 0.48
HSD17B10 Q99714 6/20 0.47
TAS1R3 Q7RTX0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765610 0.93 MAPT (0.52) MAPTCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL30765482 0.84 KDM4C (0.50) MAPTCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL23460811 0.79 F2 (0.56) CYP1A2CYP3A4CYP2C19CYP2D6ALDH1A1
SCHEMBL30765609 0.79 F2 (0.51) GAAKMT2ATDP1KDM4C
SCHEMBL30765483 0.77 F2 (0.55) ALDH1A1GAAKMT2AHSD17B10KDM4E
SCHEMBL31558534 0.77 KDM4C (0.48) MAPTCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL23460748 0.75 F2 (0.53) MAPTTSHRALDH1A1LMNAGAA
SCHEMBL30765959 0.74 F2 (0.49) MAPTCYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL23460662 0.74 F2 (0.52) MAPTCYP1A2CYP2C19CYP2D6CYP2C9
SCHEMBL23460757 0.74 F2 (0.46) MAPTCYP1A2CYP2C19CYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed